

Society for Endocrinology - Media Release



For immediate release

Society for Endocrinology releases new position statement on the use of dopamine agonists in endocrine disorders

The Society for Endocrinology has issued a new position statement concerning the use of dopamine agonists in the treatment of patients with endocrine disorders. The full statement can be viewed at:

http://www.endocrinology.org/policy/docs/07-09_Dopamine_statement.pdf

Dopamine agonists are routinely used in the treatment of pituitary disorders such as hyperprolactinaemia or acromegaly. This statement follows reports earlier this year that the use of the dopamine agonists pergolide and cabergoline in the management of Parkinson's disease is associated with cardiac valve fibrosis⁽¹⁾.

The Society for Endocrinology is the major British society representing scientists, clinicians and nurses who work with hormones. We aim to advance education and research in endocrinology for the public benefit and to promote endocrinology and hormone awareness to the wider community.

-----Ends-----

Notes for editors:

The full statement can be viewed at: http://www.endocrinology.org/policy/docs/07-09_Dopamine_statement.pdf

The Society for Endocrinology is Europe's largest national organisation promoting endocrinology and hormone awareness. For general information, please visit our website: www.endocrinology.org

Please mention the Society for Endocrinology in any story

For more information: please contact the Society for Endocrinology press office

Jennie Evans
External Relations Assistant
01454 642 230
jennie.evans@endocrinology.org

Tom Parkhill
External Relations Manager
01454 642 206
tom.parkhill@endocrinology.org

Website: <http://www.endocrinology.org/press>

References:

⁽¹⁾ Schade et al. 2007. Dopamine Agonists and the Risk of Cardiac-Valve Regurgitation. New England Journal of Medicine, 356, 29-38.